MEEX Speaker

ZAMEK-GLISZCZYNSKI Maciej, PhD

ZAMEK-GLISZCZYNSKI Maciej, PhD

Senior Fellow and Director, DMPK, GlaxoSmithKline, Collegeville, PA, USA

Biography

Maciej Zamek-Gliszczynski has 15 years of industry (Eli Lilly and GSK) experience in leading DMPK and PK/PD/clinical pharmacology aspects of oncology, endocrine/metabolic, and infectious disease programs at all stages between discovery, clinical development, and post-marketing (6 clinical candidate selections & INDs, 2 NDAs).  He is an experienced global manager, having led the Quantitative Drug Disposition group responsible for understanding victim and perpetrator DDIs for the entire GSK portfolio.  Dr. Zamek-Gliszczynski’s research is focused on PK/PD and DDI implications of drug and metabolite transport.  He is the author of >100 manuscripts and presentations on this subject (>5,000 cites, -index = 35).  He serves on the editorial boards of Pharmaceutical Research and Drug Metabolism and Disposition.  Dr. Zamek-Gliszczynski is a member of the International Transport Consortium (ITC) steering committee, was past chair of AAPS PK/PD/Drug Metabolism (PPDM) section, and he served as GSK management representative on IQ Translational ADME Leadership Group (TALG).  He has been active in organizing DMPK/clinical pharmacology meetings with ITC, ASCPT and AAPS.  Dr. Zamek-Gliszczynski lectures in graduate-level PK/PD courses and serves as external committee advisor (including as adjunct prof at UNC).  He enjoys developing scientists and has an established mentorship record at the associate scientist, junior and peer Ph.D., as well as graduate student and post-doc levels.

Webinars

Conferences